Exosome CDMO

Exosome CDMO

Exosome CDMO

GWOXI is committed to producing gold standard of pharmaceutical grade stem cell-derived exosomes. Our platform can produce pharmaceutical grade exosomes derived from a qualified stem cell source, e.g., hADSC, hWJMSC, hBMSC, sheep-WJMSC.

 
Platform description:

 

We use exclusively patented technologies to empower stem cells to secrete functional exosomes. After going through a strict isolation and purification processes, we conduct comprehensive testing to characterize the extracted exosome, ensuring its quality.

 

The testing processes include:

 

  • 1. Nanoparticle Tracking Analysis (NTA): Accurate analysis for detecting exosome size and concentration.
  • 2. Biomarker analysis: Confirm the exosomes’identity.
  • 3. Protein concentration analysis: Calculate the protein content in the final exosome formulation.
  • 4. Growth factor assay: Verify growth factor levels in exosomes.
  • 5. Stem cell characterization: Ensure the quality of stem cell sources.
  • 6. Microorganism testing: Ensure the safety of the final exosome formulation.

 

Quality Assurance:

 

Our strict quality control ensures the stability and purity of exosomes. GWOXI Stem Cell Exosomes, integrating cutting-edge technology and strict quality control, is your reliable partner in the field of regenerative medicine.

 

✅ Certified to meet international standards for cosmetic ingredients.(INCI Name)

GWOXI’s “Human Adipose-Derived Mesenchymal Stem Cell Exosomes” have received INCI New Ingredient Certification.


GWOXI Exosome

 

Service Workflow:

 

  1. 1. Consultation
    Define requirements and intended use.
  2. 2. Agreement
    Confirm specification and contract.
  3. 3. Cell Culture, Purification, and Collection
    Conduct cell expansion, exosome purification, and exosome collection.
  4. 4. QC Testing
    Conduct quality testing to characterize collected exosome.
  5. 5. Shipping and Testing Report
    Provide final product attached with comprehensive CoA.

 

For further inquiries or quotation requests, please feel free to contact us.

Press Releases

Press Releases
NEWS
  • /userfiles/images/news/251022/20251022090426346.jpg
    22
    2025
    10
    Press Releases
    Gwo Xi Stem Cell’s Diabetes Cell Therapy Product GXIPC1® Receives Phase I Trial Results Approval from Vietnam’s MOH

  • /userfiles/images/news/20250729055948126.jpg
    26
    2025
    09
    Press Releases
    GWOXI Stem Cell Secures Taiwan Invention Patent for Stem Cell-Derived Composition in Wound Healing

  • /userfiles/images/news/250909/20250924013519855.jpg
    09
    2025
    09
    Press Releases
    GWOXI Stem Cell Expands Cross-Border Collaborations — Engaging Potential Partners in Thailand